BSYI Stock Overview
BioSyntech, Inc. develops biotherapeutic thermogels for tissue repair and therapeutic delivery.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
BioSyntech, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$0.000001 |
52 Week High | US$0.000001 |
52 Week Low | US$0.000001 |
Beta | 0 |
1 Month Change | 0% |
3 Month Change | n/a |
1 Year Change | n/a |
3 Year Change | -99.96% |
5 Year Change | -99.97% |
Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
BSYI | US Biotechs | US Market | |
---|---|---|---|
7D | 0% | 0.08% | 1.9% |
1Y | n/a | 11.6% | 31.1% |
Return vs Industry: Insufficient data to determine how BSYI performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how BSYI performed against the US Market.
Price Volatility
BSYI volatility | |
---|---|
BSYI Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 11.8% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.6% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BSYI has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine BSYI's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1994 | n/a | n/a |
BioSyntech, Inc. develops biotherapeutic thermogels for tissue repair and therapeutic delivery. Its lead products in development include BST-CarGel, a biodegradable gel for cartilage repair; BST-InPod for heel pain relief; BST-DermOn for chronic wound healing; BST-Ossifil for bone filling; BST-Ossifix for bone structural support; and BST-Disc for intervertebral disc restoration. The company’s products also comprise BST-Gel-based injectable products that deliver biotherapeutics to their targeted site of action; Arthro-BST, an arthroscopic device used for the non-destructive evaluation of cartilage degradation and/or repair; and Mach-1, a micromechanical testing system for evaluating the mechanical properties of tissues and materials.
BioSyntech, Inc. Fundamentals Summary
BSYI fundamental statistics | |
---|---|
Market cap | US$116.00 |
Earnings (TTM) | -US$9.29m |
Revenue (TTM) | US$145.80k |
0.0x
P/S Ratio0.0x
P/E RatioIs BSYI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BSYI income statement (TTM) | |
---|---|
Revenue | CA$199.70k |
Cost of Revenue | CA$69.36k |
Gross Profit | CA$130.34k |
Other Expenses | CA$12.85m |
Earnings | -CA$12.72m |
Last Reported Earnings
Dec 31, 2009
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did BSYI perform over the long term?
See historical performance and comparison